AC T01932
XX
ID T01932
XX
DT 05.11.1996 (created); ewi.
DT 13.05.2013 (updated); yre.
CO Copyright (C), QIAGEN.
XX
FA RelB
XX
SY I-Rel.
XX
OS mouse, Mus musculus
OC eukaryota; animalia; metazoa; chordata; vertebrata; tetrapoda; mammalia; eutheria; rodentia; myomorpha; muridae; murinae
XX
GE G006644 Relb.
XX
HO dorsal.
XX
CL C0020; Rel; 6.1.1.2.2.
XX
SF N-terminally shortened sequence when compared with the human homolog [6];
SF no heterodimerization with c-Rel or RelA (p65) [2];
SF efficient DNA-binding requires heterodimerization [6];
SF heterodimerization occurs through the C-terminal part of the Rel domain [5];
SF the C-terminal part of the whole molecule is rich in proline, glycine, and acidic residues [6];
SF the C-terminal activating domain requires cooperation with an additional activating domain in the N-terminus comprising the leucine repeat as integral part [3];
XX
CP Mouse fibroblasts [11].
XX
FF constitutive activator in heterodimeric complexes with either NF-kappaB1 (p50) or NF-kappaB2 (p52) [2] [6];
FF activates the IkappaB-alpha gene, but is not a target for the IkappaB-alpha inhibitor and thus is not retained in the cytoplasm [2];
FF particularly high level expression in lymphoid cells [4];
FF tissue-specific gene activation in splenic B-cells and in thymocytes [1];
XX
IN T00394 NF-kappaB2-p52; human, Homo sapiens.
IN T19130 NF-kappaB2-p52; mouse, Mus musculus.
IN T19129 NF-kappaB2; mouse, Mus musculus.
IN T01923 p50; mouse, Mus musculus.
XX
MX M03882 V$RELBP50_Q3.
XX
BS R69985.
BS R69986.
XX
DR TRANSPATH: MO000019373.
DR UniProtKB: Q04863;
XX
RN [1]; RE0004522.
RX PUBMED: 7692309.
RA Lernbecher T., Mueller U., Wirth T.
RT Distinct NF-kappaB/Rel transcription factors are responsible for tissue-specific and inducible gene activation
RL Nature 365:767-770 (1993).
RN [2]; RE0004536.
RX PUBMED: 7925301.
RA Dobrzanski P., Ryseck R.-P., Bravo R.
RT Differential interactions of RelB-NF-kappaB complexes with IkappaBalpha determine pools of constitutive and inducible NF-kappaB activity
RL EMBO J. 13:4608-4616 (1994).
RN [3]; RE0004560.
RX PUBMED: 8441398.
RA Dobrzanski P., Ryseck R. P., Bravo R.
RT Both N- and C- terminal domains of RelB are required for full transactivation: role of the N-terminal leucine zipper-like motif
RL Mol. Cell. Biol. 13:1572-1582 (1993).
RN [4]; RE0004561.
RX PUBMED: 8076601.
RA Lernbecher T., Kistler B., Wirth T.
RT Two distinct mechanisms contribute to the constitutive activation of RelB in lymphoid cells
RL EMBO J. 13:4060-4069 (1994).
RN [5]; RE0004562.
RX PUBMED: 7760806.
RA Ryseck R.-P., Novotny J., Bravo R.
RT Characterization of elements determining the dimerization properties of Re1B and p50
RL Mol. Cell. Biol. 15:3100-3109 (1995).
RN [6]; RE0004563.
RX PUBMED: 1732739.
RA Ryseck R.-P., Bull P., Takamiya M., Bours V., Siebenlist U., Dobrzanski P., Bravo R.
RT RelB, a new Rel family transcription activator that can interact with p50-NF-kappa-B
RL Mol. Cell. Biol. 12:674-684 (1992).
RN [7]; RE0019149.
RX PUBMED: 7845467.
RA BURKLY L., HESSION C., OGATA L., REILLY C., MARCONI L.A., OLSON D., TIZARD R., CATE R., LO D.
RT Expression of relB is required for the development of thymic medulla and dendritic cells.
RL Nature 373:531-536 (1995).
RN [8]; RE0030779.
RX PUBMED: 12556537.
RA Muller J. R., Siebenlist U.
RT Lymphotoxin beta receptor induces sequential activation of distinct NF-kappa B factors via separate signaling pathways.
RL J. Biol. Chem. 278:12006-12 (2003).
RN [9]; RE0030792.
RX PUBMED: 12352969.
RA Claudio E., Brown K., Park S., Wang H., Siebenlist U.
RT BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells.
RL Nat. Immunol. 3:958-65 (2002).
RN [10]; RE0044053.
RX PUBMED: 15084608.
RA Liao G., Zhang M., Harhaj E. W., Sun S. C.
RT Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation
RL J. Biol. Chem. 279:26243-50 (2004).
RN [11]; RE0051710.
RX PUBMED: 15988009.
RA Yang H., Magilnick N., Lee C., Kalmaz D., Ou X., Chan J. Y., Lu S. C.
RT Nrf1 and Nrf2 regulate rat glutamate-cysteine ligase catalytic subunit transcription indirectly via NF-kappaB and AP-1.
RL Mol. Cell. Biol. 25:5933-5946 (2005).
RN [12]; RE0053845.
RX PUBMED: 12709443.
RA Derudder E., Dejardin E., Pritchard L. L., Green D. R., Korner M., Baud V.
RT RelB/p50 dimers are differentially regulated by tumor necrosis factor-alpha and lymphotoxin-beta receptor activation: critical roles for p100.
RL J. Biol. Chem. 278:23278-23284 (2003).
RN [13]; RE0054100.
RX PUBMED: 15858576.
RA Lawrence T., Bebien M., Liu G. Y., Nizet V., Karin M.
RT IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation.
RL Nature 434:1138-1143 (2005).
RN [14]; RE0054106.
RX PUBMED: 9314550.
RA Ishikawa H., Carrasco D., Claudio E., Ryseck R. P., Bravo R.
RT Gastric hyperplasia and increased proliferative responses of lymphocytes in mice lacking the COOH-terminal ankyrin domain of NF-kappaB2.
RL J. Exp. Med. 186:999-1014 (1997).
RN [15]; RE0065739.
RX PUBMED: 17548520.
RA Reiley W. W., Jin W., Lee A. J., Wright A., Wu X., Tewalt E. F., Leonard T. O., Norbury C. C., Fitzpatrick L., Zhang M., Sun S. C.
RT Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses.
RL J. Exp. Med. 204:1475-1485 (2007).
XX
//